WHO says Covid remains a global emergency but pandemic could near its end in 2023

Director-General of the World Health Organisation (WHO) Dr. Tedros Adhanom Ghebreyesus attends an ACANU briefing on global health issues, including COVID-19 pandemic and war in Ukraine in Geneva, Swit...

CDC urges immunocompromised to take precautions after Evusheld pulled

The Centers for Disease Control and Prevention on Friday urged people with weak immune systems to take extra precautions to avoid Covid after the dominant omicron subvariants knocked out a key antibod...

FDA proposal would allow gay men in monogamous relationships to donate blood

A nurse fills test tubes with blood to be tested during an American Red Cross bloodmobile in Fullerton, CA on Thursday, January 20, 2022. Paul Bersebach | Medianews Group | Getty Images The Food and D...

FDA pulls Evusheld because it’s not effective against subvariants

Evusheld (tixagevimab and cilgavimab) injection, a new COVID-19 treatment that people can take before becoming symptomatic. (Chris Sweda/Chicago Tribune/Tribune News Service via Getty Images) Chris Sw...

FDA advisors recommend using Covid omicron shots for all doses

The Food and Drug Administration’s independent advisory committee on Thursday recommended replacing Pfizer and Moderna’s original Covid vaccine used in the U.S. for everyone’s first ...

GenBioPro sues West Virginia, argues FDA preempts ban

Abortion pill manufacturer GenBioPro on Wednesday sued to overturn West Virginia’s ban on abortion because it restricts access to a medication approved by the Food and Drug Administration. The l...

FDA proposes new lead limits for baby food

Jgi/jamie Grill | Tetra Images | Getty Images The Food and Drug Administration proposed new limits Tuesday on lead in baby food, in an effort to reduce exposure to a toxin that can impair childhood de...

Inscripta Is Reimagining What The Synthetic Biology Company Of The Future Will Be

Inscripta’s team in Pleasanton, CA Inscripta Inscripta, a global leader in genome engineering, is reshaping the image of a synthetic biology company. Biomanufacturing is set to transform many industri...

Ginkgo Bioworks Fires Up Its Bio Foundry To Take On The Billion-Dollar Enzyme Market

Ginkgo Bioworks banner on the façade of the New York Stock Exchange building. Ginkgo Bioworks Ginkgo Bioworks is getting ready for another year of disrupting the entire biotech industry model with its...

FDA says most people probably need only one annual vaccine shot

Justin Sullivan | Getty Images The Food and Drug Administration has laid out a road map for what Covid-19 vaccination may look like moving forward. In a briefing document published Monday, the FDA sai...

The 1980s was the blueprint for the upcoming disinflation cycle and these are the stocks for it, strategists say

Stocks logged a third-straight losing session on Thursday as investors continue to deal with a mixed bag of economic data. That followed Wednesday’s session and extremely weak industrial production th...

7 Cheap But Risky Biotech Stocks

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%. The other most-watched exchange-traded fund that tracks the biotech sector, the...

Moderna says RSV vaccine is 84% effective at preventing disease in older adults

Moderna on Tuesday said its vaccine targeting respiratory syncytial virus is effective at preventing disease in older adults. The vaccine was 83.7% effective at preventing lower respiratory tract dise...

Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.

Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon. With real...

Pfizer Covid booster likely doesn’t carry seniors’ stroke risk: CDC

The Centers for Disease Control and Prevention on Friday said it is “very unlikely” the Pfizer omicron booster carries a risk of stroke for seniors after it launched an investigation into ...

U.S. uninsured rate fell during Covid pandemic, Medicaid, Obamacare coverage grew

The number of people in the U.S. without health insurance declined during the Covid-19 pandemic even as millions of people lost coverage through their employers due to layoffs. The uninsured rate in t...

250,000 kindergarteners are vulnerable due to drop in vaccination rate

Nearly a quarter of a million kindergartners are potentially vulnerable to measles due to a dip in vaccination coverage during the pandemic, according to the Centers for Disease Control and Prevention...

Halo Therapeutics stock drops following weak 2023 outlook

Halozyme Therapeutics Inc. HALO, -10.09% stock fell in the extended session Tuesday after the biotech drug maker’s 2023 forecast disappointed Wall Street. Halozyme shares fell as much as 8% after hour...

Bernie Sanders urges Moderna not to hike vaccine price

Sen. Bernie Sanders on Tuesday urged Moderna not to quadruple the price of its Covid-19 vaccine once distribution of the shots moves to the commercial market. In a letter to Moderna CEO Stephane Bance...

Patients would pay up to $26,500 per year for Leqembi

Few seniors with early Alzheimer’s disease will have access to the new treatment Leqembi due to its high cost and very limited coverage by Medicare. The Food and Drug Administration on Friday gr...

These 15 Dividend Aristocrat stocks have been the best income builders

The S&P Dividend Aristocrats deserve more coverage. Those are companies that have raised their dividend payouts consistently over the years — they’re dividend royalty, as it were. As a group, they...

European drugmakers including AstraZeneca pony up for U.S.-listed biopharmas

European drugmakers on Monday announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums. Anglo-Swedish AstraZeneca AZN, +1.42%   AZN, -1.26% said it’s pay...

It’s Pharma Time: Why Merck and Lilly Stock Are Buys, but not Pfizer.

My 2023 biotech outlook calls for continued momentum in name changes. I just need to figure out what the stocks will do. Last year, Respira Technologies became Qnovia. It’s run by a former tobacco exe...

AbbVie cuts earnings forecast due to milestone payments

AbbVie Inc. executives lowered their outlook for the quarter and year in a filing with the Securities and Exchange Commission late Friday, which cited research and development expenses and milestone p...

Fate Therapeutics stocks heads for record selloff after Janssen collaboration terminated and job cuts

Shares of Fate Therapeutics Inc. FATE, -61.18% plunged 56.8% in premarket trading, putting them on track for a record one-day selloff, after the biopharmaceutical company announced the termination of ...

Why Pfizer Is Pulling Back on Research Into Rare Disease, Gene Therapy

Pfizer is planning to pull back on early-stage research into treatments for rare diseases, including the development of new viral-based gene therapies, the company told employees on Thursday afternoon...

CytomX shares surge more than 50% on Moderna partnership

CytomX Therapeutics Inc. CTMX, +7.19% shares soared more than 50% in the extended session Thursday after the small biotech company announced a partnership with Moderna Inc. MRNA, -2.17% CytomX shares ...

CVS and Walgreens will sell mifepristone in pharmacies

Mifepristone (Mifeprex), one of the two drugs used in a medication abortion, is displayed at the Women’s Reproductive Clinic, which provides legal medication abortion services, in Santa Teresa, ...

Omicron XBB.1.5 is most transmissible subvariant, WHO says

XBB.1.5 strain, January 4, 2023, Suqian, Jiangsu, China. CFOTO | Future Publishing | Getty Images The XBB.1.5 omicron subvariant that’s currently dominating the U.S. is the most contagious versi...

ARK’s Cathie Wood Says Tesla Stock Has ‘Miles to Run’

Many investors have been running away from Tesla stock in recent weeks, worried about disappointing car sales and whether Elon Musk’s decision to buy Twitter has become too distracting. Cathie Wood is...

omicron XBB.1.5 is immune evasive, binds better to cells

Gilnature | Istock | Getty Images The Covid omicron XBB.1.5 variant is rapidly becoming dominant in the U.S. because it is highly immune evasive and appears more effective at binding to cells than rel...

U.S., global health officials worry about China transparency on virus spread

U.S. and global health leaders say Beijing is not sharing enough information about the spread of Covid-19 in China, leaving the international community in the dark about the scale and severity of the ...